Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Chronic Lymphocytic Leukemia and SOHO 2025

The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), Johnson & Johnson (Gold), Lilly (Silver) and BeOne Medicines (Silver).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

BTK degraders in CLL: how may these agents shape the field? 1:30
BTK degraders in CLL: how may these agents shape the field?
Nirav Niranjan Shah • 24 Sep 2025
Pirtobrutinib in R/R CLL: ongoing trials and evaluating this agent in earlier lines 1:56
Pirtobrutinib in R/R CLL: ongoing trials and evaluating this agent in earlier lines
Nirav Niranjan Shah • 24 Sep 2025
Safety & efficacy of the BTK degrader bexobrutideg in R/R CLL: results from an ongoing Phase I study 3:24
Safety & efficacy of the BTK degrader bexobrutideg in R/R CLL: results from an ongoing Phase I study
Nirav Niranjan Shah • 24 Sep 2025
Approaching frontline therapy selection for different risk groups in CLL 3:15
Approaching frontline therapy selection for different risk groups in CLL
Catherine Coombs • 9 Sep 2025
Novel therapies and clinical trial approaches for Richter’s transformation 1:35
Novel therapies and clinical trial approaches for Richter’s transformation
Catherine Coombs • 9 Sep 2025
Tailoring therapy for younger, fit patients with CLL: advice for community oncologists 2:17
Tailoring therapy for younger, fit patients with CLL: advice for community oncologists
Lydia Scarfò • 5 Sep 2025
How to approach sequencing in CLL amid expanding treatment options 1:22
How to approach sequencing in CLL amid expanding treatment options
Meghan Thompson • 5 Sep 2025
Novel agents showing promise for the treatment of double-refractory CLL 1:18
Novel agents showing promise for the treatment of double-refractory CLL
Meghan Thompson • 5 Sep 2025
Resistance in CLL: high-risk features and strategies to overcome this challenge 2:08
Resistance in CLL: high-risk features and strategies to overcome this challenge
Meghan Thompson • 5 Sep 2025
Switching to venetoclax-based therapy after progression on covalent BTKis in CLL: expert opinion 1:27
Switching to venetoclax-based therapy after progression on covalent BTKis in CLL: expert opinion
Gianluca Gaidano • 5 Sep 2025
The importance of understanding the mechanisms underlying Richter’s transformation 1:15
The importance of understanding the mechanisms underlying Richter’s transformation
Gianluca Gaidano • 5 Sep 2025
From fixed-duration regimens to novel agents: current & future perspectives on CLL treatment 2:34
From fixed-duration regimens to novel agents: current & future perspectives on CLL treatment
Lydia Scarfò • 4 Sep 2025
Advice for young investigators entering the CLL space and key areas of interest 1:43
Advice for young investigators entering the CLL space and key areas of interest
Meghan Thompson • 4 Sep 2025
MRD assessment in CLL: importance of standardizing tests & potential clinical application 3:04
MRD assessment in CLL: importance of standardizing tests & potential clinical application
Lydia Scarfò • 4 Sep 2025
The importance of integrating genetic profiling in CLL: from NGS to emerging biomarkers 1:39
The importance of integrating genetic profiling in CLL: from NGS to emerging biomarkers
Lydia Scarfò • 4 Sep 2025
Cost-effectiveness of continuous BTK inhibitors in patients with CLL: a Medicare financial analysis 2:07
Cost-effectiveness of continuous BTK inhibitors in patients with CLL: a Medicare financial analysis
Joanna Rhodes • 3 Sep 2025

The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), Johnson & Johnson (Gold), Lilly (Silver) and BeOne Medicines (Silver).

Diamond Supporter

AstraZeneca

Platinum Supporter

AbbVie

Gold Supporter

Johnson & Johnson

Silver Supporter

Lilly BeOne Medicines

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

If you are interested in becoming a supporter of The Chronic Lymphocytic Leukemia Channel, please contact us.

The content of VJHemOnc is intended for healthcare professionals